



Revenue for the nine-month period to September 30, 2018

Substantial growth in sales of Tracker kits for routine use:

up 18% over first 9 months and up 34% in Q3

Croissy-Beaubourg, October 18, 2018, 6:00pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER) a company specializing in *in vitro* diagnostics and theranostics, has today reported its consolidated revenue for the nine-month period to September 30, 2018.

<i>In thousands of euros</i>	September 30, 2018 (Nine-months)	September 30, 2017 (Nine-months)	Change
Revenue	6,515	6,837	-5%
<i>o/w Theranostics revenue</i>	2,850	3,144	-9%
<i>o/w Lisa Tracker® kit sales for routine use</i>	2,850	2,414	+18%
<i>o/w IVD revenues</i>	3,665	3,693	-1%

Sales for the third quarter of 2018 are up sharply at +9% compared to the third quarter of 2017. This performance is mainly due to the very strong growth in sales of Tracker kits for routine use, which rose by 34% over the period.

Theradiag's revenue in the nine-months period to September 30, 2018 totaled €6.5 million, down 5% on its nine-months 2017 level, compared to a 9% contraction in the first half of 2018.

Nine-months sales of Tracker kits for routine use moved up 18% from their nine-months 2017 level. Growth in Tracker sales for routine use accelerated from 8% in the first, to 15% in the second and 34% in the third quarter.

As in the previous quarter, total theranostics revenue declined by 9% because no non-recurring theranostics revenue was recorded in the first nine months of the year. In contrast, substantial revenue was received in the same period of 2017 under agreements with pharmaceutical groups.

IVD revenue remained stable at September 30, 2018.

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of *in vitro* diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases and cancer. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. The Company is based in Marne-la-Vallée, near Paris, and has over 65 employees.

For more information about Theradiag, please visit our website: www.theradiag.com

ALTER
EURONEXT
GROWTH



Theradiag

Investor Relations

Fabienne François

CFO

Tel.: +33 (0)1 64 62 10 12

contact@theradiag.com

NewCap

Financial Communications

& Investor Relations

Valentine Brouchet

Tel.: +33 (0)1 44 71 94 94

theradiag@newcap.eu

Alize RP

Press Relations

Caroline Carmagnol

Tel.: +33 (0)1 44 54 36 64

theradiag@alizerp.com